Drugs / NANT-008
last change Dec 2023 re-read 2 minutes ago

NANT-008

Developed for
pancreatic adenocarcinoma
Investigated by
NantPharma, LLC

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03127124 Feb 2018 → Dec 2023 pancreatic adenocarcinoma NantPharma, LLC Withdrawn No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NANT-008 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03127124